Understanding of the regulation of cholesterol metabolism and handling in the liver is central in treatment of biliary diseases, hyperlipoproteinaemias and atherosclerosis. Against this background, the Forum on Lipids in Clinical Medicine organized a symposium, chaired by Dr P H E Groot (Smith Kline & French, Welwyn) and Professor R H Dowling (Guy's Hospital, London) , in which an international group of experts on cholesterol metabolism, bile acid synthesis and bile formation participated. Topics included the regulation of the enzymes involved in cholesterol metabolism and bile acid synthesis, the mechanisms of bile acid and biliary lipid transport as well as various clinical problems associated with disturbances in bile formation.
The symposium was opened with a presentation by Dr K E Suckling (Smith Kline & French, UK) entitled 'Plasma lipoproteins, hepatic cholesterol pools and bile acid synthesis'. Hepatic unesterified cholesterol is derived from de novo synthesis in liver, from various lipoproteins, taken up by the liver as well as from the pool of cholestery1 esters, stored in the liver. Dr Suckling discussed the concept of compartmentation of cholesterol metabolism in the liver in which specific pools of cholesterol may be present as substrate for acyl-CoA:cholesterol acyltransferase (ACAT)or cholesterol 7a-hydroxylase and also as a regulatory pool for expression of the genes for HMG-CoA reductase and the LDL receptor. Studies to reveal the interrelationships between these possible pools using specific inhibitors of ACAT and cholesterol 7a-hydroxylase in hepatocyte cultures Were described. The regulation of cholesterol 7ahydroxylase, the key enzyme in the conversion of cholesterol into bile acids, was discussed in presentations from Dr H J Kempen (Gaubius Institute TNO, The Netherlands) and Dr K Botham (Royal Veterinary College, UK). Dr Kempen showed that the enzyme was seven times more active in perivenous hepatocytes when compared with periportal cells. This could be due to bile acid effects as periportal cells are exposed to high portal concentrations of bile acids. HMG-CoAreductase showed an opposite gradient posing questions about the alleged role of newly-synthesized cholesterol as major substrate for bile acid synthesis. Also discussed were experiments in rat hepatocytes showing strong stimulatory effects of corticosteroids (lOx) on Tahydroxylase activity. Perhaps the most important regulation of bile acid synthesis in vivo is by feedback inhibition exerted by bile acids transported to the liver via the portal vein. Interestingly, attempts to demonstrate such an effect in vitro in rat hepatocytes have been unsuccessful, probably due to a fast loss of the capacity of hepatocytes to take up bile acids. Using pig hepatocytes, Dr Kempen and his colleagues have now been able to demonstrate the expected feedback inhibition in vitro. Therefore pig hepatocytes may be the model of choice for in vitro studies on bile acid metabolism. Dr Botham summarized evidence for the reversible phosphorylation of cholesterol 'lohydroxylase and showed data in rat hepatocytes indicating that the enzyme can be activated by cAMP dependent phosphorylation. Evidence was also found for cAMP dependent stimulation of taurocholic acid uptake in these cells.
The proteins involved in bile acid transport in rat liver were further discussed by Professor G Kurz (University of Freiburg, GFR). Using bile acid derivatives carrying photolabile groups, Dr Kurz has identified two peptides (MW 48K and 46K), involved in sinusoidal bile acid uptake. Another peptide (MW lOOK), present in the bile canalicular membrane, was shown to be involved in bile acid secretion. Labelling of this peptide was not found in preparations of freshly isolated hepatocytes, indicating that these cells have lost their ability for bile acid secretion. The secretion of biliary lipids was further discussed by Dr R Coleman (University of Birmingham) who indicated that although bile acid and biliary lipid secretion into bile are interrelated their secretion can be dissociated from one another under certain experimental conditions. Valproic acid, iodipamin, ampicillin and other compounds were shown to inhibit biliary lipid secretion with little or no effect on bile acid secretion while kinetic experiments indicated that bile acids are secreted prior to biliary lipids. It was suggested that bile acids are initially pumped into the canalicular lumen where they process specific domains of the canalicular membrane thereby causing this membrane to vesiculate into the canalicular lumen. Under normal circumstances these domains are then replenished by biliary-type lipid brought in vesicular form from the cell interior. Evidence for this model for biliary lipid secretion was obtained from studies in livers exposed to bile acids and other detergents by retrograde biliary injection.
At low bile acid secretion rates, bile contains lipids with a relatively high cholesterol: phospholipid ratio and this ratio is decreased as the flow through the liver of bile acids increases, especially with hydrophobic bile acid species. Therefore the relationships between biliary lipid and bile acid secretion are complex and biliary cholesterol secretion may have two components, one dependent and one independent of the hepatic bile acid flow.
The afternoon session, chaired by Professor R H Dowling (Guy's Hospital, London), was dedicated to the more clinical aspects. This session was opened with a presentation by Dr G J Somjen (Ichilow Hospital, Tel Aviv, Israel) on the physical form of biliary lipids in bile. In the early eighties Dr Somjen demonstrated by quasi elastic light scattering and electron microscopy the presence in hepatic and gall bladder bile of small unilamellar vesicles composed of phospholipids and cholesterol. The presence of other carriers of cholesterol in bile, in addition to mixed micelles of bile acids, phospholipids and cholesterol, will be important for the understanding gallstone formation. Using size exclusion chromatography in the presence of 10 mM sodium cholate, Dr Somjen was able to separate mixed micelles from vesicular lipids and he concluded from analyses of a large number of hepatic biles that up to 79% of bile cholesterol is associated with vesicles. Furthermore, in the more concentrated gallbladder bile, multilaminar structures were found as major carriers of cholesterol. Dr Somjen concluded with the provocative statement that mixed micelles barely contribute to the solubilization of cholesterol in bile.
Dr J M Graham (St George's Hospital, London) discussed the intrahepatic transport of biliary lipids in cholelithiasis and obesity. From liver biopsies, taken from patients with gallstone disease and normals, Dr Graham has isolated several vesicle fractions. One of these vesicular fractions had an enzyme profile resembling both the endoplasmic reticulum (ER)and the bile canalicular (BC)membrane and this fraction was regarded as a likely candidate involved in the transport of cholesterol and phospholipid from the ER to the BC membrane. Only this fraction and the membranes of the BC showed a raised cholesterol: phospholipid molar ratio in patients with gallstone disease. Interestingly, these ratios showed strong positive correlations with the specific activity of hepatic HMG-CoA reductase, the rate-limiting enzyme in de novo cholesterol synthesis, and with the cholesterol: phospholipid molar ratios in bile. These data further suggest that the BC membrane is intimately involved in the secretion of cholesterol and phospholipids into bile and would be in line with the concepts discussed by Dr Coleman, in which bile acids secreted into the bile canaliculi induce a vesicle budding-off from domains of the BC membrane.
Professor K Einarsson (Karolinska Institute, Stockholm) discussed the effects of treatment of patients with hypercholesterolaemia, gallstone or Crohn's disease on various enzymes involved in cholesterol metabolism in liver biopsies. Cholestyramine therapy or ileal resection increased the hepatic HMG-CoA reductase, cholesterol-Zohydroxylase, ACAT and LDL receptor activity while pravastatin decreased the catalytically active HMG-CoA reductase activity and increased LDL receptor levels. Chenodeoxycholic acid administration to gallstone patients decreased HMG-CoA reductase, 7a-hydroxylase as well as the LDL receptors. No changes were seen during ursodeoxycholic acid therapy. In Crohn's disease patients there was a positive relation between the length of resected ileum and hepatic 7a-hydroxylase and HMG-CoA reductase activities. These data show that man reacts to interventions in cholesterol metabolism in a way to be predicted from animal studies.
The symposium ended with a presentation by Professor R H Dowling (Guy's Hospital, London) who overviewed the area of treatment of gallstone disease by oral bile acid therapy, lithotripsy and in situ solubilization using organic solvents.
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